ArticleThe Journal of antimicrobial chemotherapy2025
Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sepsis in Frail Older Adults: Tailored Antimicrobial Stewardship and Individualized Care Approach.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
BACKGROUND AND
objectivesBloodstream infections (BSIs) caused by carbapenemase-resistant Klebsiella pneumoniae (CR-Kp) are associated with high morbidity and mortality, particularly in frail patients. Identifying frailty upon hospital admission may improve clinical decision-making and outcomes. This study evaluates the Frailty Index Laboratory (FI-Lab) as a predictive tool for adverse outcomes in patients with CR-Kp BSIs.
methodsThis retrospective cohort study was conducted between January 2020 and September 2024 at the Policlinico Universitario di Bari. Frailty was assessed using FI-Lab, derived from 35 laboratory parameters measured within 96 h of admission. Outcomes included all-cause mortality, 28 day mortality and relapse, with FI-Lab predictive accuracy evaluated via ROC curve analysis.
resultsA total of 182 patients with CR-Kp BSIs were included, of whom 48 died (26.3%). Non-survivors had significantly higher FI-Lab scores than survivors (0.66 ± 0.10 versus 0.33 ± 0.16, P < 0.0001). FI-Lab demonstrated excellent predictive accuracy for mortality (AUC = 0.94), 28 day mortality (AUC = 0.87) and relapse (AUC = 0.87). Each 0.10-point increase in FI-Lab was associated with a higher risk of mortality (HR = 2.07), 28 day mortality (HR = 1.86) and relapse (HR = 1.52).
conclusionsThe FI-Lab proved to be a simple and robust tool for early frailty assessment in patients with CR-Kp BSIs. Further studies are needed to validate these findings and explore the broader applicability of FI-Lab in managing infections in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.